Brought to you by 
British Biotech merges with RiboTargets
27 Apr 2021
Executive Summary
Following talks that began in January, British Biotech (matrix metalloproteinase inhibitors, MMPIs) has agreed to merge with RiboTargets (anti-infectives and oncology drugs). RiboTargets' CEO Simon Sturge becomes CEO of the new biotech company, which will be 50.01% owned by the shareholders of BB, and 49.99% by RiboTargets.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Acquisition
- Intra-Biotech Deal
- Partial Acquisition
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
British Biotech merges with RiboTargets
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice